百利天恒创新双抗ADC治疗肺癌研究结果出炉 在非小细胞肺癌领域具有临床价值

Core Insights - BaiLi TianHeng's drug, iza-bren (EGFR×HER3 bispecific ADC), has been recognized at the 2025 World Lung Cancer Conference (WCLC) for its significant clinical value in treating EGFR-mutant lung cancer [1] - The drug has shown promising results in two studies, indicating its potential to change clinical practice [1] Group 1: Study Results - The first study involved 154 patients treated with iza-bren (2.5 mg/kg D1D8Q3W) combined with Osimertinib, achieving a 100% objective response rate (ORR) and a 92.1% progression-free survival (PFS) rate at 12 months [2] - The second study reported a median PFS exceeding 12 months for patients with advanced or metastatic solid tumors treated with iza-bren, with a 94% tumor shrinkage rate and an ORR of 66% [3] Group 2: Clinical Development - Iza-bren is the first and only EGFR×HER3 bispecific ADC currently in Phase III clinical trials globally, with nearly 40 clinical trials ongoing in China and the U.S. for various tumor types [4] - The drug has been prioritized for review by the Center for Drug Evaluation (CDE) for use in recurrent or metastatic nasopharyngeal carcinoma patients [4]